Revolution Medicines Inc at JPMorgan Healthcare Conference (Virtual) Transcript
All right. Good evening, and thanks for sticking with us for our JPMorgan Healthcare Conference. I'm Eric Joseph, senior biotech analyst at the firm. And our next presenting company is Revolution Medicines. And it's my pleasure to welcome CEO, Mark Goldsmith, to tell us a little bit about the company. (Operator Instructions)
With that, Mark, thanks again for sharing some of your time with us.
Thank you, Eric, for the opportunity to introduce Revolution Medicines.
Slide 2. Revolution Medicines is a clinical-stage precision oncology company focused on large unmet medical needs in RAS-addicted cancers, representing a very significant share of all human cancers. Our science-driven strategy includes targeted therapeutics organized into 2 portfolios: First, our RAS(ON) inhibitors, deriving from an innovative technology platform, are unique compounds that target diverse oncogenic RAS
| Access to All Earning Calls and Stock Analysis | |
| 30-Year Financial on one screen | |
| All-in-one Stock Screener with unlimited filters | |
| Customizable Stock Dashboard | |
| Real Time Insider Trading Transactions | |
| 8,000+ Institutional investors’ 13F holdings | |
| Powerful Excel Add-in and Google sheets Add-on | |
| All data downloadable | |
| Quick customer support | |
| And much more... |
Trustpilot
We'd love to learn more about your experiences on GuruFocus.com and how we can improve!
Take Survey
